

# Financial Tear Sheet

## Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

## Transfer Agent

### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(http://www.computershare.com)

## Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

## Stock Performance: CTIC (Nasdaq)

**Exchange** NASDAQ CM (US Dollar)

**Price** **\$3.99**

**Change (%)** ▼ 0.06 (1.48%)

**Volume** 135,263

**52 Week Low** \$2.45

**Market Cap** \$234,830,583

**Rolling EPS** -1.29

**PE Ratio** 0

**Shares Outstanding** 57,982,860

Data as of 03/16/18 4:00 p.m. ET



## Recent Headlines & Events

Mar 09, 2018 - 7:05 a.m.  
 CTI BioPharma to Present at Upcoming Investor Conferences  
 (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2337284)

Mar 09, 2018 - 7:00 a.m.  
 CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology  
 (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2337281)

Mar 07, 2018 - 4:01 p.m.  
 CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results  
 (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2336850)

Date	Title
03/20/18 10:55 a.m. ET	<b>CTI BioPharma Corp at Oppenheimer and Co. 28th Annual Healthcare Conference</b> (phoenix.zhtml?c=92775&p=irol-EventDetails&EventId=5269431)
03/28/18 10:00 a.m. ET	<b>CTI BioPharma Corp at 17th Annual Needham Healthcare Conference</b> (phoenix.zhtml?c=92775&p=irol-EventDetails&EventId=5269432)

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	79	81.12	41.4	23,986,948
Mutual Fund	21	3.30	1.9	1,107,533
Insider *	7	2.77	1.2	691,405

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	6,929,690	12.0	-1,666,667	02/09/18
OrbiMed Advisors, LLC	5,000,000	8.6	0	12/31/17
New Enterprise Associates (NEA)	3,750,000	6.5	3,750,000	02/08/18
Stonepine Capital Management, LLC	2,150,000	3.7	315,162	01/11/18
NB Public Equity Komplementar ApS	1,356,635	2.3	90,000	12/31/16
The Vanguard Group, Inc.	850,881	1.5	-225,168	12/31/17
Sphera Funds Management Ltd.	833,633	1.4	0	12/31/17
Renaissance Technologies LLC	609,849	1.1	198,700	12/31/17
BlackRock Institutional Trust Company, N.A.	406,748	0.7	7,586	12/31/17
Kennedy Capital Management, Inc.	246,189	0.4	246,189	12/31/17

*Data provided by Nasdaq. Minimum 15 minutes delayed.*